SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit shares are under heavy pressure after the company's fiscal 2027 guidance badly missed estimates, triggering a double-digit sell-off as investors react to a slowdown in growth, weak Mailchimp performance, and pricing issues driving TurboTax customers away. While retail sentiment on Stocktwits has flipped to 'extremely bullish' with some traders calling it a buying opportunity, the broader conversation centers on whether AI threats to core software products and the CEO's admission of customer losses justify the bearish outlook.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors brace for the semiconductor giant's highly anticipated earnings report, which serves as a major bellwether for the broader AI sector. While there is strong demand for data center infrastructure, the community is actively debating whether the stock will break its trend of post-earnings volatility, with many traders closely watching guidance and the potential for a directional shift.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

PSKY is trending as the Paramount-WBD merger remains stalled by California AG Bonta's antitrust lawsuit, with retail sentiment turning increasingly bullish on the deal and critical of Bonta's tactics, especially after Iowa's AG threatened Supreme Court action. The community sees the legal fight as political obstruction and is focusing on the potential for the merger to close despite the challenges.

Sharplink, Inc. is an institutional-grade Ethereum treasury platform that provides public market investors with exposure to Ether. It operates through the following segments: ETH Treasury Management and Affiliate Marketing. The ETH Treasury Management segment focuses on the accumulation and active management of ETH as a long-term treasury asset. The Affiliate Marketing segment focuses on performance-based customer acquisition services for sportsbooks and online casino gaming operators worldwide. The company was founded in 2019 and is headquartered in Miami, FL.

Sharplink Inc.

SharpLink Gaming Ltd

SBET is trending as traders highlight its discounted Ethereum treasury value and anticipated upside from potential crypto-positive legislation, with technicals signaling a possible breakout above $7.50 after closing a key volume gap, while bullish sentiment focuses on the stock's undervaluation relative to its ETH holdings and institutional accumulation.

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

Sentiment is split as bullish traders highlight OpenAI-driven lab automation cost cuts and DARPA ICE Phase III progress, while skeptics point to ongoing cash burn and dilution risks.

FuelCell Energy, Inc. is an American clean energy technology company that delivers continuous, scalable baseload power for mission-critical applications globally. It engages in the development, design, production, construction, operation, and servicing of high-temperature fuel cells for clean electric power generation. The company’s fuel cell systems generate electricity directly at the point of use, enabling reliable, low-emission power for data centers, industrial facilities, utilities, and distributed generation customers. FuelCell Energy delivers commercially proven, modular, utility-scale systems backed by global fuel cell deployments approaching one gigawatt. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

Retail sentiment is laser-focused on the upcoming Q3 earnings report and conference call as the pivotal near-term catalyst, with traders debating whether management will finally announce a major data-center contract or strategic partnership. The broader clean-energy and AI-infrastructure sector context, including the ExxonMobil carbon-capture tie-in and competitive comparisons to Bloom Energy, frames the debate between bulls expecting a fundamental breakout and bears citing dilution and execution risk.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

ASST is surging as Bitcoin's breakout fuels a short squeeze on the Bitcoin-treasury stock, with the community highlighting lofty short interest and the CEO's aggressive BTC purchases as the trigger. Bulls are calling this the start of a parabolic move while shorts scramble to cover, with the stock outperforming peers like MSTR.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Traders are focused on Nvidia's earnings and the upcoming PCE inflation print, with geopolitical headlines on a possible US-Iran ceasefire also driving sentiment. The community is debating whether the AI trade can decouple from the broader market, while key support and resistance levels are being watched.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

KURA is surging after the CEO made two large open-market stock purchases, signaling insider confidence. Retail sentiment is highly bullish, with traders highlighting the drug's commercial momentum and a potential acquisition by partner Kyowa Kirin as key catalysts.

Flowers Foods, Inc. engages in the production and marketing of packaged bakery foods. It offers breads, buns, rolls, snack items, bagels, English muffins, and tortillas and are sold under a variety of brand names, including Nature’s Own, Dave’s Killer Bread, Wonder, Canyon Bakehouse, Tastykake, and Mrs. Freshley’s. The company was founded by William Howard Flowers, Sr. and Joseph Hampton Flowers, Jr. in 1919 and is headquartered in Thomasville, GA.

Flowers Foods, Inc.

FLO is trending after a sharp post-earnings selloff, driven by a Q2 miss with declining volumes, compressed margins, and full-year guidance cuts. Traders are split between value buyers eyeing the high dividend yield and low valuation, and skeptics warning of continued deterioration and potential dividend risk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?

Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.

Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?

BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.

Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

Denali Therapeutics narrows Q2 loss as Avlayah sales top estimates, with strong launch traction and pipeline updates shaping its outlook.

Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

Denali Therapeutics (DNLI) delivered earnings and revenue surprises of +5.56% and +143.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Will Recent Setbacks Impact Growth Prospects of DNLI Stock?

Denali Therapeutics gains FDA approval for Avlayah, but pipeline setbacks and partner exits raise fresh questions as key clinical programs continue.

DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?

Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partnership changes and trial setbacks remain in focus.

Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II

RGNX shares jump after FDA alignment on next steps for Navsunli, paving the way for a planned MPS II BLA resubmission in Q3 2026.

Denali to Sell Priority Review Voucher for $195M Cash Boost

DNLI will gain $195M from selling its Rare Pediatric Disease PRV, adding non-dilutive capital to advance its clinical portfolio and growth plans.

Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos

Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos...

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Denali Therapeutics Inc

BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial

Equity

Bullish Sentiment

Rallies more than 5%

Modest gain (0-5%)

Modest decline (0-5%)

Drops more than 5%

Nvidia ($NVDA) reports earnings Wednesday, August 26, with options markets pricing in a roughly 5-7% post-earnings move. How do you think Nvidia's stock reacts to earnings? Vote and explain your reasoning in the comments.

Nvidia ($NVDA) reports earnings Wednesday, with options markets pricing in a 5-7% move. How do you think the stock reacts?

Stocktwits

) reports earnings Wednesday, with options markets pricing in a 5-7% move. How do you think the stock reacts?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.41	--	--	N/A
Q2 '26	-$0.51	-$0.68	-32.54%	MISSED
Q1 '26	-$0.72	-$0.69	4.61%	BEAT
Q4 '25	-$0.74	-$0.73	0.93%	BEAT
Q3 '25	-$0.75	-$0.74	1.02%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings